In patients treated with ranibizumab no significant effects could be observed with a baseline VEGF of 59.0 pg/ml , 54.0 pg/ml at 7 days ( p = 0.776 ) and 58.5 pg/ml at 4 weeks of follow-up ( p = 0.670 ) .